Risperdal and Effexor xr drug interactions for women aged 20-29 (a phase IV clinical study of FDA data)

< 1 month:

1. Blood prolactin increased
2. Drug withdrawal syndrome (interfere with normal social, occupational, or other functioning. are not due to another medical condition, drug use, or discontinuation)
3. Galactorrhoea (secretion of breast milk in men)
4. Leukopenia (less number of white blood cells in blood)
5. Suicide attempt
6. Weight increased
7. Asthenia (weakness)
8. Dyspnoea (difficult or laboured respiration)
9. Eosinophilia (eosinophil count in the peripheral blood exceeds)
10. Hypoaesthesia (reduced sense of touch or sensation)

1 - 6 months:

1. Obesity (having too much body fat)
2. Pancreatitis (inflammation of pancreas)
3. Arthritis (form of joint disorder that involves inflammation of one or more joints)
4. Blood cholesterol increased
5. Cholecystitis chronic (long lasting infection of gallbladder)
6. Cytolytic hepatitis (dissolution or destruction of a liver cell)
7. Dehydration (dryness resulting from the removal of water)
8. Glycosylated haemoglobin increased
9. Hyperglycaemia (high blood sugar)
10. Hypertension (high blood pressure)

6 - 12 months:

n/a

1 - 2 years:

n/a

2 - 5 years:

1. Diabetes mellitus inadequate control
2. Gestational diabetes (diabetes in pregnancy)
3. Type 2 diabetes mellitus

5 - 10 years:

n/a

10+ years:

n/a

not specified:

1. Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
2. Diabetes mellitus inadequate control
3. Type 2 diabetes mellitus
4. Cholecystitis chronic (long lasting infection of gallbladder)
5. Heart rate increased
6. Metabolic syndrome (a combination of the medical disorders that, when occurring together, increase the risk of developing cardiovascular disease)
7. Pancreatitis (inflammation of pancreas)
8. Pulmonary embolism (blockage of the main artery of the lung)
9. Sexually inappropriate behaviour
10. Weight increased